JP2024528893A5 - - Google Patents

Info

Publication number
JP2024528893A5
JP2024528893A5 JP2024505093A JP2024505093A JP2024528893A5 JP 2024528893 A5 JP2024528893 A5 JP 2024528893A5 JP 2024505093 A JP2024505093 A JP 2024505093A JP 2024505093 A JP2024505093 A JP 2024505093A JP 2024528893 A5 JP2024528893 A5 JP 2024528893A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
macular degeneration
disease
composition according
apom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528893A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/038278 external-priority patent/WO2023009479A1/en
Publication of JP2024528893A publication Critical patent/JP2024528893A/ja
Publication of JP2024528893A5 publication Critical patent/JP2024528893A5/ja
Pending legal-status Critical Current

Links

JP2024505093A 2021-07-28 2022-07-26 網膜神経変性を予防するための組成物及び方法 Pending JP2024528893A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163226756P 2021-07-28 2021-07-28
US63/226,756 2021-07-28
PCT/US2022/038278 WO2023009479A1 (en) 2021-07-28 2022-07-26 Compositions and methods for prevention of retinal neurodegeneration

Publications (2)

Publication Number Publication Date
JP2024528893A JP2024528893A (ja) 2024-08-01
JP2024528893A5 true JP2024528893A5 (https=) 2025-07-29

Family

ID=85087191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505093A Pending JP2024528893A (ja) 2021-07-28 2022-07-26 網膜神経変性を予防するための組成物及び方法

Country Status (5)

Country Link
US (1) US20240350582A1 (https=)
EP (1) EP4376868A4 (https=)
JP (1) JP2024528893A (https=)
CA (1) CA3227609A1 (https=)
WO (1) WO2023009479A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592268B2 (en) * 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
EP3800191B1 (en) * 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
EP3668551A4 (en) * 2017-08-15 2021-04-14 Children's Medical Center Corporation APOM FC FUSION PROTEINS AND USES THEREOF
CN109303782A (zh) * 2018-10-24 2019-02-05 厦门大学 Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用

Similar Documents

Publication Publication Date Title
JP2024028658A5 (https=)
JP2021050226A5 (https=)
JP2022514269A5 (https=)
Krause et al. Summary of antibody workshop: the role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases
JP2023071670A5 (https=)
JP2023143940A5 (https=)
JP2024528893A5 (https=)
JP2011519950A5 (https=)
JP2002326936A5 (https=)
Brett-Smith The poisonous child
Bauer et al. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis: comparison with prior macrolide treatment
JP2024543259A5 (https=)
Ackerman et al. Hypersensitivity reactions to drugs in acquired immunodeficiency syndrome
Williams The swetenesse of confection: a recipe for spiritual health in London, British Library, Additional MS 61823, The Book of Margery Kempe
CN309797287S (zh) 儿童牙刷(麻花、棒棒锤)
Kannai et al. To come full circle
Fogarty et al. Sustained 24-h Bronchodilation with Indacaterol Once-Daily in COPD: A 26-Week Efficacy and Safety Study.
Karaulov et al. Use of azoximer bromide for treatment of children's inflammatory infections of respiratory system: a meta-analysis of controlled clinical studies
Ferreira et al. HIV/AIDS, the pandemic that went from initial despair to a contained threat
Scibona et al. A Phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab’) 2 fragments in healthy volunteers
CN309730624S (zh) 玩具(双环扭扭乐)
Coltman et al. A faithful friend is the medicine of life
Lu et al. Ebola origin and therapies
Shankar et al. POS-147 CLINICAL PROFILE AND OUTCOME OF C3 GLOMERULOPATHY AND COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY-AN EXPERIENCE FROM A TERTIARY CARE CENTRE IN SOUTH INDIA
Heart et al. Report